BZYR (Burzynski Research Institute) OCF Margin %: 0.00% (As of Nov. 2025)


What is Burzynski Research Institute OCF Margin %?

Burzynski Research Institute BZYR OCF Margin % is 0.00% as of Nov. 2025. Among 960 Biotechnology companies, Burzynski Research Institute ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Burzynski Research Institute's Cash Flow from Operations for the three months ended in Nov. 2025 was $-0.82 Mil. Burzynski Research Institute's Revenue for the three months ended in Nov. 2025 was $0.00 Mil. Therefore, Burzynski Research Institute's OCF Margin % for the quarter that ended in Nov. 2025 was 0.00%.

As of today, Burzynski Research Institute's current OCF Yield % is -32.17%.

The historical rank and industry rank for Burzynski Research Institute's OCF Margin % or its related term are showing as below:


BZYR's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Burzynski Research Institute OCF Margin % Related Terms

Burzynski Research Institute OCF Margin % Historical Data

* Premium members only.

The historical data trend for Burzynski Research Institute's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burzynski Research Institute OCF Margin % Chart

Burzynski Research Institute Annual Data
Trend Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Burzynski Research Institute Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Burzynski Research Institute OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Burzynski Research Institute's OCF Margin for the fiscal year that ended in Feb. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Feb. 2025 )/Revenue (A: Feb. 2025 )
=-0.389/0
= %

Burzynski Research Institute's OCF Margin for the quarter that ended in Nov. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Nov. 2025 )/Revenue (Q: Nov. 2025 )
=-0.823/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Burzynski Research Institute (BZYR) has a OCF Margin % of 0.00% as of Nov. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Burzynski Research Institute and its competitors. According to the industry distribution chart, Burzynski Research Institute ranks #999999 out of 960 companies in the Biotechnology industry.
Is Burzynski Research Institute's OCF Margin % too high?
Burzynski Research Institute's current OCF Margin % is 0.00%. Based on the distribution chart, Burzynski Research Institute ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Burzynski Research Institute's OCF Margin % compare to CLSDQ and ZVSA?
According to the Biotechnology industry distribution chart, Burzynski Research Institute ranks #999999 out of 960 companies for OCF Margin %. This places Burzynski Research Institute in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Burzynski Research Institute and its competitors. Burzynski Research Institute's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burzynski Research Institute stock overvalued right now?
Burzynski Research Institute (BZYR) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Burzynski Research Institute (BZYR), the current OCF Margin % is 0.00% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Burzynski Research Institute Business Description

Address 9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.